The cell-free DNA (cfDNA) blood collection tube market is ripe with opportunities driven by the rise in lifestyle-related ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand ...

Natera Inc. is conducting a study titled ‘EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND).’ The study aims to develop and validate a single-gene Non-Invasive Prenatal ...

Founded by Dr. Thomas Crisman, Genome Based Diagnostics has focused on developing accessible and reliable testing solutions ...

A label-free nanopore platform uses programmable DNA circuits to build versatile molecular logic gates, forming a universal basis for scalable DNA computing and advanced biosensing applications.

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive care options, covering treatments for acute myeloid leukemia (AML), ...

A major US study reveals that marijuana use leaves measurable chemical traces in DNA, altering genes related to mental health ...

Considering pregnancy later in life? Find out what “advanced maternal age” really means, the risks to consider and how women ...

Brains with chronic traumatic encephalopathy (CTE) show DNA damage similar to Alzheimer’s. Study links genetic stress to ...

Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ:NTRA) develops and commercializes genetic ...

By restructuring a common chemotherapy drug, scientists increased its potency by 20,000 times. In a significant step forward ...